DECK 7 - General Data Protection Regulations (GDPR)

May 23, 2018

DECK 7 is committed to protecting our customers' data and safeguarding their privacy.

Spotlight

Alnylam Pharmaceuticals

We are developing an innovative, entirely new class of medicines called “RNAi therapeutics” to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNA interference (RNAi), and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope.

OTHER VIDEOS

Changing the world of drug formulation

video | August 15, 2022

Manufacturing drugs for paediatric applications comes with a unique set of challenges. Notably, the need to counteract the bitterness of active pharmaceutical ingredients, and enhance solubility to reduce the risk of delayed onset of action and local tissue injury....

Watch Now

Denver's SmartTab combines modern technology with everyday drug capsule

video | August 11, 2022

A startup pharmaceutical company in Denver is working on a way to deliver much-needed medication through a high-tech capsule. You're In Good Company with SmartTab....

Watch Now

Pharmacy Management System Project in Python Source Code

video | May 21, 2022

Pharmacy Management System Project in Python Source Code What is Pharmacy Management System Project in Python...

Watch Now

AI accelerated drug discovery

video | May 20, 2022

AI accelerated drug discovery, allowing for a fast-track discovery and repurposing of existing molecule, intelligent clinical design and coupled with in-house manufacturing....

Watch Now

Spotlight

Alnylam Pharmaceuticals

We are developing an innovative, entirely new class of medicines called “RNAi therapeutics” to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNA interference (RNAi), and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope.

Events